Diseases [C] » Infections [C01] » Bacterial Infections and Mycoses » Bacterial Infections » Gram-Positive Bacterial Infections » Actinomycetales Infections » Mycobacterium Infections » Tuberculosis » Tuberculosis, Multidrug-Resistant
Description
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. MeSH
Hierarchy View
Subtype Terms (1)
Extensively Drug-Resistant Tuberculosis
15 drugs (13 approved, 2 experimental)
Approved Indicated Drugs (1)
Phase 3 Indicated Drugs (8)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (60)
Almaty City Tuberculosis Dispensary, Almaty, Kazakhstan
Don McKenzie Hospitals, Kwazulu Natal, South Africa
Doris Goodwin Hospitals, Kwazulu Natal, South Africa
Drugs for Neglected Diseases Initiative
Ganesh Shankar Vidyarthi Memorial Medical College
Hackensack University Medical Center
Institute of Tropical Medicine, Belgium
Interactive Research and Development
JSC Scientific Center for Anti-infectious Drugs
Karaganda State Medical University
National Center for Tuberculosis and Lung Diseases, Georgia
National Center for Tuberculosis Problems, Kazakhstan
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Regional Anti-TB Dispensary of Karagandy Oblast, Kazakhstan
Republican Research and Practical Centre for Pulmonology and Tuberculosis
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital
Republican specialised scientific-practical medical centre, Tashkent
Organization Involved with Phase 2 Indications (18)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.